Feasibility of Tracheobronchial Reconstruction Using Allogenic Aortic Patch in Children

November 16, 2025 updated by: National Taiwan University Hospital
Feasibility and safety of repairing tracheal and bronchial defects in infants and children using cryopreserved donor aortic patches.

Study Overview

Detailed Description

This trial plans to use cryopreserved donor aortic tissue patches to repair and treat pediatric patients with end-stage, life-threatening or severely disabling tracheal diseases who have not responded to conventional conservative therapies or lack sufficient native tracheal tissue for tracheal defect reconstruction.

Study Type

Interventional

Enrollment (Estimated)

5

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan
        • Taiwan National Taiwan University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Meeting any of the following conditions, and being unsuitable for standard end-to-end tracheal anastomosis or lacking sufficient native tracheal tissue for defect reconstruction:

  1. Congenital tracheal malformations: including congenital tracheomalacia, congenital tracheobronchial anomalies, complete tracheal rings, etc., with severe clinical respiratory symptoms and recommended for treatment after evaluation.
  2. Acquired tracheal stenosis: including tracheal narrowing caused by disease, endotracheal intubation, or postoperative scar formation, with severe clinical respiratory symptoms and recommended for treatment after evaluation.
  3. Tracheal injury or tissue loss due to trauma or burns requiring surgical repair.
  4. Tracheal tumors: reconstruction of tracheal tissue after resection of benign or malignant tumors.
  5. The term "severe clinical respiratory symptoms" includes:

    1. Dependence on mechanical ventilation for more than 1 month due to airway narrowing or defect, with inability to wean.
    2. Airway stenosis exceeding 50% (confirmed by bronchoscopy or CT imaging), accompanied by persistent stridor, inspiratory dyspnea, or suprasternal/substernal retractions, causing impairment of daily activities or feeding difficulties.
    3. Unilateral or bilateral lung atelectasis persisting for more than 1 month due to tracheal or bronchial stenosis, with no sign of recovery.
    4. Recurrent post-obstructive pneumonia (≥3 episodes) in one or both lungs caused by tracheal or bronchial stenosis, requiring hospitalization for treatment.

Exclusion Criteria:

  1. Inability to obtain legal informed consent from the lawful guardian.
  2. Locally invasive tracheal tumors that cannot be completely resected surgically.
  3. Malignant solid tumors with distant metastases that cannot be completely resected surgically or controlled with medication.
  4. Presence of severe immunodeficiency (e.g., congenital immunodeficiency, HIV infection, ongoing chemotherapy, or recovery period after bone marrow transplantation).
  5. Presence of major congenital diseases or chromosomal abnormalities (e.g., Trisomy 13, Trisomy 18) with extremely poor prognosis as assessed clinically.
  6. End-stage organ failure (e.g., persistent multiple organ failure, irreversible cardiopulmonary failure, or brain death).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cryopreserved aorta
After resection of tracheal or bronchial lesion, reconstruct the airway with cryopreserved aortic allograft.
After resection of the tracheal or bronchial lesion with standard surgical techniques, the airway gap is reconstructed with a segment of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
90-day Mortality
Time Frame: Postoperative 90 days
Survival status of patients within 90 days after surgery. This primary endpoint evaluates patient mortality, as patients undergoing this type of surgery often have a high short-term risk of death.
Postoperative 90 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anastomotic Leakage
Time Frame: Within 90 days postoperatively
Incidence of anastomotic leakage at the tracheal anastomosis site.
Within 90 days postoperatively
Pneumonia
Time Frame: Within 90 days postoperatively
Incidence of postoperative pneumonia.
Within 90 days postoperatively
Difficult Extubation
Time Frame: Within 90 days postoperatively
Occurrence of difficulties in extubation after surgery.
Within 90 days postoperatively
Granulation Tissue Obstruction
Time Frame: Within 90 days postoperatively
Incidence of airway obstruction due to granulation tissue formation.
Within 90 days postoperatively
Stenosis Caused by Scar Fibrosis and Related Complications
Time Frame: Within 90 days postoperatively
Occurrence of airway stenosis due to scar fibrosis or other related complications.
Within 90 days postoperatively

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Long-term Clinical Follow-up
Time Frame: At least 1 year postoperatively; infants and young children followed until at least puberty
Patients will undergo long-term follow-up including medical history review, physical examination, and imaging studies as clinically indicated (including but not limited to X-ray, CT scan, and bronchoscopy) to monitor long-term airway status and overall health.
At least 1 year postoperatively; infants and young children followed until at least puberty

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 9, 2025

Primary Completion (Estimated)

January 31, 2028

Study Completion (Estimated)

January 31, 2028

Study Registration Dates

First Submitted

September 12, 2025

First Submitted That Met QC Criteria

November 16, 2025

First Posted (Actual)

November 20, 2025

Study Record Updates

Last Update Posted (Actual)

November 20, 2025

Last Update Submitted That Met QC Criteria

November 16, 2025

Last Verified

October 1, 2025

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tracheal Stenosis

Clinical Trials on Cryopreserved aorta

Subscribe